Professional Development
Business / Events

Delaware’s second ChemTech Con will look at COVID-19 and beyond

From supply chain optimization to machine learning, the two day virtual event will discuss the "new normal in digital transformation." It returns Oct. 7 and 8.

A closer look at chemtech in Delaware. (Photo by Pexels user Chokniti Khongchum, used under a Creative Commons license)

Delaware Sustainable Chemistry Alliance launched its inaugural ChemTech Conference last year with a focus on the evolution of the commodity chemical industry. On Oct. 7 and 8, the two-day virtual event returns, this time with a focus on the successes and challenges the COVID-19 pandemic has brought to the chemtech industry.

With a theme of “Beyond COVID — Macro Trends & The New Normal in Digital Transformation,” the event will kick off with a McKinsey & Company keynote and will include these panels and topics:

  • Machine Learning & Manufacturing
  • Formulation Models & Innovation
  • Predictive Analytics & Innovation
  • Predictive Analytics & New Business Models
  • Cybersecurity & Industrial Control Systems
  • Supply Chain Optimization

Panelists will be representative of some of the state’s biggest players in the industry, including DuPont, Merck, FMC and Eastman Chemicals.

The virtual conference will include one optional in-person networking event — a social on the Kalmar Nyckel at the Copeland Maritime Center with drinks and hors d’oeuvres on the evening of the 7th.

Ticket holders to the ChemTech Conference will have access to videos of all of the sessions for 30 days after the event.

Tickets and info
Companies: FMC Corporation / DuPont / Merck
Engagement

Join the conversation!

Find news, events, jobs and people who share your interests on Technical.ly's open community Slack

Trending

What company leaders need to know about the CTA and required reporting

How venture capital is changing, and why it matters

Why the DOJ chose New Jersey for the Apple antitrust lawsuit

Delaware Money Moves: Incyte and AstraZeneca put billions into cancer pharm acquisitions

Technically Media